Latest Bisphosphonate Stories
The long-awaited results of the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer, the AZURE trial, will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 8-12.
EAST HANOVER, N.J., Dec.
NEW YORK, Nov.
Forteo, a drug produced by Eli Lilly and Co. and used for osteoporosis, has been found to be able to re-grow bone in jaws damaged by severe bone-destroying conditions called osteonecrosis and periodontitis, doctors reported on Saturday.
THOUSAND OAKS, Calif., Oct.
Labeling change adds warning about possible risks of long-term use of osteoporosis drugs SILVER SPRING, Md., Oct. 13 /PRNewswire-USNewswire/ -- The U.S.
BURLINGTON, Mass., Sept.
PRAGUE, Sept. 24 /PRNewswire/ -- Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP).
People who take oral bisphosphonates for bone disease over five years may be doubling their risk of developing oesophageal cancer (cancer of the gullet), according to a new study published on bmj.com today.
Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.